People pose with syringe with needle in front of displayed Pfizer logo in this illustration ... Dolsten held senior leadership roles at Wyeth, Boehringer Ingelheim, and AstraZeneca, where he ...

Veeva Systems (NYSE: VEEV) today announced Veeva SiteVault CTMS, a clinical trial management system for research sites that ...

Boehringer Ingelheim is a biopharmaceutical company active in both human and animal health. As one of the industry's top investors in Research and Development, the company focuses on developing ...

STOCKHOLM, March 13, 2025 (GLOBE NEWSWIRE) -- Salipro Biotech AB, a Swedish biotech company specialising in the stabilisation of challenging drug targets, today announced a research and license ...

Cognizant, as the prime system integrator, began the Boehringer Ingelheim project by codeveloping a program roadmap, agile methodology, and implementation workflow. The overall scope of the ...

Top 20 biopharma goes live with Veeva Development Cloud to speed the delivery of treatments for currently incurable diseases "Together with Veeva, Boehringer has advanced its approach to clinical ...

Boehringer Ingelheim and Veeva (VEEV) Systems have announced the launch of Boehringer’s One Medicine Platform, powered by the successful implementation of Veeva Development Cloud. They first ...

Top 20 biopharma goes live with Veeva Development Cloud to speed the delivery of treatments for currently incurable diseases INGELHEIM, Germany and BARCELONA, Spain, March 11, 2025 /PRNewswire/ -- ...

(Image Credits: Pixabay) Boehringer Ingelheim’s blockbuster diabetes drug, Empagliflozin, is now off-patent in India, paving the way for domestic drugmakers to launch generic versions.

A comprehensive study from Karolinska Institutet shows that people with fatty liver disease have almost twice the mortality ...

A research led by Sergio P. Acebrón, Researcher Ikerbasque at the UPV/EHU, develops a key tool to visualize the immune response to abnormal DNA, opening new avenues for the treatment of diseases.